Liita Care ApS
LIITA Care is a late-stage consumer-health biotechnology company focused on inhalation-based self-care therapies for respiratory conditions. The organization develops a dry salt microparticle inhalation platform intended to produce a targeted hyper-osmotic effect in the airways and a handheld metered-dose inhaler device approved for distribution in the EU. LIITA Care conducts randomized clinical trials, academic collaborations, post-market surveillance, and pursues regional distribution and licensing partnerships, including civilian and defense/dual-use applications.
Industries
Nr. of Employees
small (1-50)
Liita Care ApS
Products
Metered-dose sodium chloride particle inhaler (handheld)
Handheld metered-dose inhaler that dispenses micronized sodium chloride particles intended for delivery to the upper and lower airways to aid mucus clearance and relieve respiratory irritation.
Metered-dose sodium chloride particle inhaler (handheld)
Handheld metered-dose inhaler that dispenses micronized sodium chloride particles intended for delivery to the upper and lower airways to aid mucus clearance and relieve respiratory irritation.
Services
Negotiation and establishment of regional and global licensing and distribution agreements for inhalation platforms and line extensions; supports co-branding and pharmacy distribution.
Collaborative clinical research projects with academic and clinical partners, including grant-supported studies and sponsored investigations aimed at validating therapeutic effects and mechanisms.
Negotiation and establishment of regional and global licensing and distribution agreements for inhalation platforms and line extensions; supports co-branding and pharmacy distribution.
Collaborative clinical research projects with academic and clinical partners, including grant-supported studies and sponsored investigations aimed at validating therapeutic effects and mechanisms.
Expertise Areas
- Clinical trial management
- Inhalation therapy formulation and device development
- Medical device regulatory compliance and CE marking
- Antiviral and respiratory disease research
Key Technologies
- Dry powder inhalation of sodium chloride microparticles
- Targeted aerosol particle deposition design
- Hyper-osmotic mucosal modulation
- Metered-dose particle delivery mechanisms
News & Updates
Clinical investigations into the inhalation treatment platform published in a peer-reviewed journal; company links to the publication on its website.
Clinical results, including randomized trial findings on cough resolution, selected for presentation at the European Respiratory Society Congress.
Announcement of an exclusive distribution agreement with a Danish pharmacy cooperative to market the inhaler through pharmacy channels.
Announcement of availability in Baltic markets through a regional partner under a co-branded distribution arrangement.
Selected to participate in a national dual-use growth accelerator program to explore defense and humanitarian applications of the inhalation technology.
Reports of deployment of inhaler units to military users in Ukraine and participation in defense-sector events and accelerator programs.
Clinical investigations into the inhalation treatment platform published in a peer-reviewed journal; company links to the publication on its website.
Clinical results, including randomized trial findings on cough resolution, selected for presentation at the European Respiratory Society Congress.
Announcement of an exclusive distribution agreement with a Danish pharmacy cooperative to market the inhaler through pharmacy channels.
Announcement of availability in Baltic markets through a regional partner under a co-branded distribution arrangement.
Selected to participate in a national dual-use growth accelerator program to explore defense and humanitarian applications of the inhalation technology.
Reports of deployment of inhaler units to military users in Ukraine and participation in defense-sector events and accelerator programs.